Late Life Asparagine Endopeptidase Inhibition Extends Lifespan in Mice
Key claim: Inhibiting asparagine endopeptidase starting late in life at 18 months extends median lifespan in mice by four months.
Abstract
Few interventions have been demonstrated to slow aging or address age-related damage to a sufficient degree to extend mouse life span by 15% or more if applied starting at a late age. The requirement to start late in life cuts down the field of possibilities quite dramatically. Today’s open access paper stakes a claim for inhibition of asparagine endopeptidase activity to be included in the small number of interventions capable of this sort of outcome. The researchers started treating mice at 18 months of age, roughly equivalent to 50-something in humans, and saw a four month gain in median survival, from 24 to 28 months. For comparison, this is in the same ballpark as the results of rapamycin treatment started in late life in mice. […]
Why this matters
[animal-model] The reported four-month median lifespan extension concerns treatment begun at 18 months, making intervention timing central to this finding rather than lifelong preventive exposure. The supplied evidence is a news report of a mouse study, not human outcome evidence; primary-study methods, uncertainty, and replication remain unresolved here.